Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) will host a webcast on May 2, 2022, at 5:00am PT to discuss the topline results from the Saturn-2 Phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for treating Demodex blepharitis. This trial is part of Tarsus's mission to revolutionize treatment in eye care with innovative therapies. In addition to TP-03, the company is advancing other investigational medicines targeting high unmet needs in eye care and infectious disease prevention. The webcast will be available for 90 days post-event.

Positive

• Scheduled webcast to present topline results from the Saturn-2 Phase 3 trial for TP-03.
• TP-03 is aimed at addressing Demodex blepharitis, a condition with high unmet medical need.
• Tarsus has multiple investigational medicines in clinical trials across various therapeutic categories.

Negative

• None.

IRVINE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, will hold a webcast on Monday, May 2, 2022 at 5:00am PT/8:00am ET to review the topline results from the Saturn-2 Phase 3 trial for TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis and provide a brief corporate update.

Webcast Information

The webcast can be accessed at the events section of the Tarsus website. After the live webcast, the event will remain archived on the Tarsus website at https://ir.tarsusrx.com/ for 90 days.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. In addition, Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1b clinical trial.

Contacts:
Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
akemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

What is Tarsus Pharmaceuticals announcing on May 2, 2022?

Tarsus Pharmaceuticals will present topline results from the Saturn-2 Phase 3 trial of TP-03 for treating Demodex blepharitis.

What is TP-03 and its significance?

TP-03 (lotilaner ophthalmic solution, 0.25%) is Tarsus's lead product candidate for treating Demodex blepharitis, targeting a high unmet need in eye care.

How can I access the Tarsus Pharmaceuticals webcast?

The webcast can be accessed via the events section of the Tarsus website and will be archived for 90 days after the live event.

What is the focus of Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals focuses on addressing unmet needs in eye care and other areas through innovative therapeutic solutions.